Dulaglutide, developed by Eli Lilly, is a once-weekly GLP-1 RA like albiglutide, but with some key differences
Outside this range, bonds cleave and deamidation accelerates
Their main mechanism of action is to make users feel satiated more quickly, reducing overall food intake as well as consumption of alcohol and tobacco
F., Leggio, L., & Farokhnia, M
Theres also this recent headline: Which is a touchy subject and I dont want to settle the European regulators investigation (notoriously not overly sensitive about things), but Id venture to say that the psychological impact of obesity and the psychiatric side effects associated with changing body type including dysmorphia and eating disorders probably indicate that this is not a side effect of the drug but rather a side effect of the primary effect of the drug, in a small subset of patients